Gene:
LMNB2
lamin B2

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  LMN2
Alternate Symbols:  None
PharmGKB Accession Id: PA30404

Details

Cytogenetic Location: chr19 : p13.3 - p13.3
GP mRNA Boundary: chr19 : 2428164 - 2456958
GP Gene Boundary: chr19 : 2425164 - 2466958
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. caspase cascade in apoptosis - (BioCarta via Pathway Interaction Database)
  2. tnfr1 signaling pathway - (BioCarta via Pathway Interaction Database)

Publications related to LMNB2: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sequencing of the reannotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy. American journal of human genetics. 2006. Hegele Robert A, et al. PubMed

LinkOuts

Entrez Gene:
84823
OMIM:
150341
608709
UCSC Genome Browser:
NM_032737
RefSeq RNA:
NM_032737
RefSeq Protein:
NP_116126
RefSeq DNA:
AC_000062
AC_000151
NC_000019
NG_008355
NT_011255
NW_001838476
NW_927173
UniProtKB:
LMNB2_HUMAN (Q03252)
Ensembl:
ENSG00000176619
GenAtlas:
LMNB2
GeneCard:
LMNB2
MutDB:
LMNB2
ALFRED:
LO243053R
HuGE:
LMNB2
Comparative Toxicogenomics Database:
84823
ModBase:
Q03252
HumanCyc Gene:
HS01920
HGNC:
6638

Common Searches